Shineco (NASDAQ:SISI – Get Free Report) and Synaptogenix (NASDAQ:TAOX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Valuation & Earnings
This table compares Shineco and Synaptogenix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
| Synaptogenix | $772,499.00 | 37.78 | -$28.74 million | ($3.85) | -1.01 |
Volatility & Risk
Shineco has a beta of -1.76, indicating that its stock price is 276% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and target prices for Shineco and Synaptogenix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
| Synaptogenix | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Shineco and Synaptogenix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shineco | -380.55% | -79.89% | -33.01% |
| Synaptogenix | -2,153.97% | -128.51% | -97.54% |
Institutional and Insider Ownership
4.1% of Shineco shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 0.0% of Shineco shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Shineco beats Synaptogenix on 6 of the 11 factors compared between the two stocks.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
About Synaptogenix
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Receive News & Ratings for Shineco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shineco and related companies with MarketBeat.com's FREE daily email newsletter.
